<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>As many as 34 patients having stage II-III atherosclerotic dyscirculatory <z:hpo ids='HP_0001298'>encephalopathy</z:hpo> with coexisting <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> in the presence of stenosing and occlusive lesions of major brain arteries were evaluated for effects pentoxiphyllin and corglycon on the clinical course of this medical condition as well as systemic and cerebral haemodynamics </plain></SENT>
<SENT sid="1" pm="."><plain>In this series, 82.7 percent of patients derived benefit from a single intravenous infusion of pentoxiphyllin and corglycon and course treatment with these drug preparation that was evidenced by an improvement in the parameters of systemic and cerebral hemodynamics and regression of neurologic symptomatology </plain></SENT>
<SENT sid="2" pm="."><plain>The results of the studies made permit recommending pentoxiphyllin in combination with corglycon for treatment of those DE patients with eukinetic and hypokinetic types systemic haemodynamics, whereas pentoxiphyllin alone--for those with hyperkinetic type of haemodynamics, taking into consideration its cardiodepressive effects </plain></SENT>
</text></document>